Suchergebnisse - "O'Connor, Owen A"

PubPharm (287)

71

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

enthalten in: Blood | 2017

von Deng, C. | Lipstein, M. | Scotto, L. | +15

72

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

enthalten in: British journal of haematology | 2017

von Sawas, A. | Farber, C. | Schreeder, M. | +10

73

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

enthalten in: British journal of haematology | 2017

von Sawas, A. | Farber, C. | Schreeder, M. | +10

74

Post‐transplant lymphoproliferative disorder: a heterogeneous conundrum – response to Weisenburger DD & Gross TG

enthalten in: British journal of haematology | 2017

von Radeski, D. | Montanari, F. | Alobeid, B. | +2

75

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

enthalten in: Journal of hematology & oncology | 2016

von Falchi, L. | Sawas, A. | Deng, C. | +6

76

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

enthalten in: Journal of hematology & oncology | 2016

von Falchi, L. | Sawas, A. | Deng, C. | +6

77

Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment

enthalten in: British journal of clinical pharmacology | 2016

von Zhao, B. | Chen, R. | O'Connor, O. | +7

78

Will new drugs change the standard of care for patients with mantle cell lymphoma?

enthalten in: Expert review of anticancer therapy | 2016

von Colbourn, D. | Amengual, J. | Deng, C. | +2

79

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2016

von Shah, J. | Jakubowiak, A. | O'Connor, O. | +13

80

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

enthalten in: Clinical cancer research | 2016

von Shah, J. | Jakubowiak, A. | O'Connor, O. | +13